Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of BFI-751 vs Stelara in Healthy Volunteers
NCT04843631Phase 1Completed
- Sponsor
- BioFactura
- Start
- Apr 2021
- Primary completion
- Dec 2021
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of ustekinumab biosimilar BFI-751 in psoriasis (3 arms), sponsored by BioFactura. Primary endpoints: Maximum Observed Serum Concentration at Day 85, Time to Maximum Observed Serum Concentration at Day 85 and 6 more. Started Apr 2021; status: completed.
02
Drugs
ustekinumab biosimilar BFI-751
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT04843631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04843631.